Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

Let's give him the benefit of the doubt (until he lies to shareholders like O'Connor did). He's definitely made some material changes with the reduction in workforce, more focused restrained use of cash that was previously treated like it grew on trees and now prioritizing the need to partner and bring in non-dilutive cash rather than the misguided strategy of "spend significant resources to develop AXAL as far as possible internally in order to get a bigger deal later".